Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 285 entries
View as:

Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06702618 Org: User:
Start: 01/31/25 End: 12/31/26 Due: 12/31/27

Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06897579 Org: User:
Start: 04/07/25 End: 04/30/27 Due: 04/30/28

A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor

Phase: N/A Priority: Normal
NCT ID: NCT05021367 Org: User:
Start: 09/23/21 End: 10/31/25 Due: 10/31/26

A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)

Phase: N/A Priority: Normal
NCT ID: NCT04234607 Org: User:
Start: 01/31/20 End: 12/31/22 Due: 12/31/23

A Bioequivalence Study of Capecitabine Tablets

Phase: N/A Priority: Normal
NCT ID: NCT01846650 Org: User:
Start: 12/31/12 End: 06/30/13 Due: 06/30/14

Study of Anlotinib in Patients With Primary Malignant Bone Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03527888 Org: User:
Start: 01/31/18 End: 12/31/19 Due: 12/31/20

A Bioequivalence Study of Sunitinib Malate Capsules.

Phase: N/A Priority: Normal
NCT ID: NCT05800106 Org: User:
Start: 12/04/18 End: 01/12/19 Due: 01/12/20

A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis

Phase: N/A Priority: Normal
NCT ID: NCT05011019 Org: User:
Start: 09/07/21 End: 02/02/24 Due: 02/02/25

A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx

Phase: N/A Priority: Normal
NCT ID: NCT05068206 Org: User:
Start: 10/08/21 End: 06/30/24 Due: 06/30/25

A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Phase: N/A Priority: Normal
NCT ID: NCT06527144 Org: User:
Start: 09/14/24 End: 03/06/25 Due: 03/06/26

A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT05970432 Org: User:
Start: 06/19/23 End: 03/31/24 Due: 03/31/25

Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT05985187 Org: User:
Start: 10/20/20 End: 12/31/23 Due: 12/31/24

The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06434467 Org: User:
Start: 05/31/24 End: 05/31/26 Due: 05/31/27

Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05994365 Org: User:
Start: 08/31/23 End: 12/31/28 Due: 12/31/29

Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT05353179 Org: User:
Start: 06/30/22 End: 10/31/22 Due: 10/31/23

Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers

Phase: N/A Priority: Normal
NCT ID: NCT05333276 Org: User:
Start: 07/29/22 End: 05/31/24 Due: 05/31/25

Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT03974594 Org: User:
Start: 05/21/19 End: 07/16/19 Due: 07/16/20

Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03983928 Org: User:
Start: 06/03/19 End: 12/31/20 Due: 12/31/21

A Clinical Trial of Safety and Tolerance of TQH3821 Tablets in Adult Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05380934 Org: User:
Start: 05/29/22 End: 05/20/23 Due: 05/20/24

A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms

Phase: N/A Priority: Normal
NCT ID: NCT04339400 Org: User:
Start: 11/20/18 End: 06/30/21 Due: 06/30/22

A Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04623333 Org: User:
Start: 11/30/20 End: 06/30/23 Due: 06/30/24

A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT05121350 Org: User:
Start: 03/31/22 End: 06/30/24 Due: 06/30/25

A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)

Phase: N/A Priority: Normal
NCT ID: NCT04925141 Org: User:
Start: 05/10/16 End: 12/06/19 Due: 12/06/20

TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma

Phase: N/A Priority: Normal
NCT ID: NCT05496569 Org: User:
Start: 12/31/22 End: 12/31/24 Due: 12/31/25

A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets

Phase: N/A Priority: Normal
NCT ID: NCT06507891 Org: User:
Start: 07/06/20 End: 06/04/24 Due: 06/04/25